Joshua Harridine

Rituximab therapy achieves comparable remission to cyclophosphamide in ANCA-associated vasculitis with severe KIDNEY involvement

Abstract Introduction The RAVE/RITUXIVAS trials established rituximab (RTX) therapy in ANCA-associated vasculitis (AAV). However, RAVE excluded patients with severe renal involvement (creatinine > 354 µmol/L). Whilst RITUXIVAS did not, treatment included RTX with 2 cyclophosphami...